Business Monitor International


Belgium Pharmaceuticals & Healthcare Report

Published 18 December 2014

  • 111 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Belgium Pharmaceuticals & Healthcare Report

BMI View: Belgium boasts a fair and transparent regulatory regime which, in addition to a progressive business environment, has been instrumental in retaining the country's appeal as a strategic regional hub for multinational drugmakers. Notwithstanding a particularly sluggish recovery from the e urozone crisis, per capita pharmaceutical expenditure remain s markedly above the regional average and widespread access to healthcare will continue to support already high demand for treatments . While fiscal pressures threaten the sustainability of this system, i n the short term, measures to contain drug prices and restrain public spending will be softened by the constitutional obligation to provide access to high quality health services. Over the long term, however , with policy decisions in Belgium relying on consensus among a host of fragmented stakeholders and public agencies, drugmakers will find the direction of future regulation particularly difficult to discern.

Headline Expenditure Projections

  • Pharmaceuticals: From EUR5.78bn (USD7.19bn) in 2014 to EUR5.79bn (USD7.20bn) in 2015; -0.04% in local currency terms and -6.7% in US dollar terms. Local currency forecast above Q414.

  • Healthcare: From EUR42.75bn (USD53.22bn) to EUR43.85bn (US54.59bn) 2015; +2.6% in local currency terms and -4.3% in US dollar terms. Local currency forecast above Q414 .

Risk/Reward Rating:

In our Q115 Pharmaceutical Risk/Reward Index Belgium remains ranked sixth out of the fifteen markets surveyed in the Western European region. Despite average reward scores, Belgium is markedly outperformed by the growth potential of markets such as the UK and Germany.

Key Trends and Developments

  • Belgian drugmaker UCB in November 2014 entered an agreement with private equity groups Advent International and Avista Capital Partners to divest its US-based specialty generics business Kremers Urban. Subject to regulatory approval and other customary closing conditions, UCB will receive...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generic Companies By Market Share, 2010
26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2012-2018)
33
Other Healthcare Data
34
Key Risks To BMI's Forecast Scenario
35
Macroeconomic Forecasts
36
Economic Analysis
36
Table: Belgium - Economic Activity
39
Industry Risk Reward Ratings
40
Western Europe Risk/Reward Ratings
40
Belgium Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
47
Industry Trends And Developments
49
Epidemiology
49
Public Health Developments
50
Healthcare Sector
51
Healthcare Insurance
52
Healthcare Financing
53
Medical Tourism
54
Research And Development
55
Table: R&D Investment By Chemical & Life Science Industries, 2005-2010
55
Clinical Trials
59
Regulatory Development
61
Pharmaceutical Advertising
62
Regulatory Developments
62
Intellectual Property Issues
63
Pricing Regime
64
Reimbursement Regime
65
Table: Reimbursements By Category, 2009
67
Table: Price Build-Up For OTC Medicines
69
Competitive Landscape
70
Pharmaceutical Sector
70
Recent Company Developments
71
Pharmaceutical Distribution
74
Table: Members Of AnGR, 2011
74
Pharmaceutical Retail Sector
75
Table: Members Of OPHACO, 2011
76
Company Profile
78
UCB Pharma
78
Solvay (Abbott)
86
Janssen Pharmaceutica
89
Omega Pharma
92
Galapagos (GSK)
96
GlaxoSmithKline
102
Pfizer
105
Novartis
108
Sanofi
110
Merck & Co
113
Demographic Forecast
115
Table: Belgium's Population By Age Group, 1990-2020 ('000)
116
Table: Belgium's Population By Age Group, 1990-2020 (% of total)
117
Table: Belgium's Key Population Ratios, 1990-2020
118
Table: Belgium's Rural And Urban Population, 1990-2020
118
Glossary
119
Methodology
121
Pharmaceutical Expenditure Forecast Model
121
Healthcare Expenditure Forecast Model
121
Notes On Methodology
122
Risk/Reward Ratings Methodology
123
Ratings Overview
124
Table: Pharmaceutical Risk/Reward Ratings Indicators
124
Indicator Weightings
125

The Belgium Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgium pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Belgium, to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Belgian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belgium.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc